Claims for Patent: 7,374,758

✉ Email this page to a colleague

Summary for Patent: 7,374,758

Title:	Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
Inventor(s):	Papadopoulos; Nicholas J. (Lagrangeville, NY), Davis; Samuel (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	11/016,503
Patent Claims:	1. A method of inhibiting vascular endothelial growth factor (VEGF) activity in a mammal, comprising: administering a pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises (a) a VEGF antagonist, and (b) a pharmaceutically acceptable carrier wherein the VEGF antagonist comprises a dimeric fusion polypeptide comprising two fusion polypeptides, each fusion polypeptide comprising: (i) a VEGF receptor component consisting of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1 or human Flt4; and (ii) a multimerizing component, wherein VEGF activity is inhibited. 2. The method of claim 1, wherein the mammal is a human. 3. A method of inhibiting tumor growth in a mammal, comprising: administering a pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises (a) a VEGF antagonist, and (b) a pharmaceutically acceptable carrier wherein the VEGF antagonist comprises a dimeric fusion polypeptide comprising two fusion polypeptides, each fusion polypeptide comprising: (i) a VEGF receptor component consisting of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1 or human Flt4; and (ii) a multimerizing component, wherein tumor growth is inhibited.

Details for Patent 7,374,758

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Sign Up	2019-06-08
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Sign Up	2019-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,374,758

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Argentina	044938	⤷ Sign Up
Austria	E293164	⤷ Sign Up
Austria	E417928	⤷ Sign Up
Austria	E427962	⤷ Sign Up
Austria	E486091	⤷ Sign Up
Australia	2004252175	⤷ Sign Up
Australia	2005201365	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.